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LETTERS
Fruit bats in the genus Rousettus are widely distrib-
uted throughout Southeast Asia, South China, and the en-
tire Indian subcontinent and have had positive serologic 
results for Ebola viruses in these regions (7–9), indicating 
that these bats play a role in the circulation of filoviruses in 
Asia. The possibility of new emerging filovirus-associated 
diseases in the continent emphasizes the need for further 
investigation of these animals.
The study was supported by NSFC-Yunnan Province Joint 
Fund (U1036601), National “973” Program (grant no. 
2012CB722501) and National “863” Program (grant no. 
2012AA022006) to C.T. Sampling of bats was approved by 
the Administrative Committee on Animal Welfare of Academy 
of Military Medical Sciences, China (Laboratory Animal Care 
and Use Committee Authorization, permit number: JSY-
DW-2010-02).
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To the Editor: Bacillus Calmette-Guérin (BCG) vac-
cine is one of the most commonly used vaccines for tu-
berculosis (TB) worldwide (1). The original BCG strain 
was developed in 1921. Numerous strains have since 
been developed, and 5 strains, including Danish SSI 1331 
(Statens Serum Institute, Copenhagen, Denmark), ac-
count for >90% of BCG vaccine used. Each strain 
has unique characteristics and a different reactogenic-
ity profile (2). The most common severe adverse events 
related to BCG vaccination are nonsuppurative and sup-
purative lymphadenitis.
In the country of Georgia, BCG vaccine is adminis-
tered routinely to infants (estimated coverage 96%); the 
National Center for Disease Control and Public Health 
receives its vaccine supply from the United Nations Chil-
dren’s Fund and is responsible for countrywide distribution. 
Before 2012, Russian BCG-I (Bulbio, Sofia, Bulgaria) and 
Danish SSI 1331 strains were used (≈50% each). Shortly 
after a change to exclusive use of the Danish 1331 strain 
during 2012–2013, an increasing number of BCG-related 
lymphadenitis cases were reported to the National Center 
for Tuberculosis and Lung Diseases (NCTLD). We aimed 
to quantify the increase in cases of BCG lymphadenitis and 
to evaluate clinical management of the cases. The Institu-
tional Review Boards of Emory University (Atlanta, GA, 
USA) and the National Center for Disease Control and 
Public Health approved the study.
Medical chart abstraction was conducted for all infants 
with BCG lymphadenitis either reported to the NCTLD or 
found by inquiry of pediatricians at the largest children’s 
hospital in the country during January 2012–July 2013. 
We used national surveillance data to obtain the number of 
live-born infants.
BCG vaccine is given intradermally over the deltoid 
muscle on the left arm to infants within 5 days after birth at 
the maternity hospital. BCG lymphadenitis was clinically 
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defined as ipsilateral axillary lymph node enlargement 
developing within 2 years after vaccination. If the pa-
tient was brought for care to the NCTLD, a sample was 
obtained through aspiration for acid-fast bacilli smear; 
culture; and, if necessary, drug-susceptibility testing (3). 
Although treatment was at the discretion of clinicians, na-
tional TB program treatment guidelines did not include 
management of BCG-related adverse events.
During 2007–2011, six cases of BCG lymphadenitis 
were reported to the NCTLD. During the 19-month study 
period, we found 23 cases of BCG lymphadenitis: 15 re-
ported to the NCTLD and 8 diagnosed at the Tbilisi chil-
dren’s hospital and ascertained by inquiry (Table). In all 
cases, a 0.05-mL dose of Danish SSI BCG vaccine (series 
111003A and 111021A) was used. The 15 infants from 
the NCTLD were vaccinated at 8 maternity hospitals: 6 
in Tbilisi and 2 in outside regions. A total of 14,230 live-
born infants were registered at hospitals reporting BCG 
lymphadenitis in 2012. Based on the following calcula-
tion—16 cases/(14,230 live-born infants × 96% vaccina-
tion coverage)—the estimated prevalence of BCG-related 
suppurative lymphadenitis in 2012 was 1.12 cases per 
1,000 infants.
Median time from BCG vaccination to onset of lymph-
adenitis was 5 months (range 1–15 months). No patients 
had systemic signs or symptoms.
After a change in BCG vaccine strains in Georgia to 
the exclusive use of BCG SSI vaccine, we found a sub-
stantial increase in the known prevalence of BCG-associ-
ated lymphadenitis. We found 23 cases of BCG-associat-
ed lymphadenitis during a 19-month period, ≈4 times the 
number of reported cases during the prior 5 years, when 
multiple vaccine strains were used. The estimated preva-
lence of suppurative lymphadenitis (1.12 cases/1,000 in-
fants) was higher than the expected rate of <1/1,000 given 
by the manufacturer (4). Our rate is probably an underes-
timation, given a mainly passive system of surveillance. 
Prior studies in various countries have similarly shown 
increased BCG lymphadenitis with the introduction of the 
BCG SSI vaccine (5–7).
We found different approaches to treatment of BCG-
associated lymphadenitis depending on where care was 
received. Physicians at the NCTLD prescribed first-line 
anti-TB medications, including pyrazinamide, whereas 
patients managed at the children’s hospital were treated 
with either surgical excision or a conservative watch-and-
wait approach. Although no official treatment guideline 
exist for suppurative BCG-associated lymphadenitis, a re-
cent meta-analysis found no benefit to using anti-TB med-
ications (8). Furthermore, Mycobacterium bovis is inher-
ently resistant to pyrazinamide. A randomized controlled 











lymph	node,	mm Culture Surgery 
Drugs 
used 
NCTLD,	n	=	15         
 1 F 2012	Jan	9 5 20 Pos No R,	I,	P Completed 
 2 M 2012	Dec	19 5 14 ND No R,	I,	P Completed 
 3 F 2012	Jul	2 9 40 NA No R,	I,	P Completed 
 4 F 2012	May	31 12 28 NA No R,	I,	P Completed 
 5 M 2012	Jul	25 4 15 NA No R,	I,	P Computed 
 6 F 2012	Aug	16 1 15 NA No R,	I,	P Defaulted 
 7 M 2012	Feb	7 2 22 NA No R,	I,	P Completed 
 8 M 2011	Nov	28 3 24 NA No R,	I,	P Defaulted 
 9 M 2012	Jul	9 2 18 NA No R,	I,	P Defaulted 
 10 M 2012	Aug	7 7 23 NA Yes R,	I,	E Unknown 
 11 M 2012	May	10 4 56 NA No R,	I,	P Completed 
 12 M 2012	Nov	13 6 60 NA No R,	I,	P Completed 
 13 M 2012	Oct	1 2 11 Pos Yes R,	I Completed 
 14 M 2012	Feb	22 9 24 NA No R,	I,	P,	E Completed 
 15 F 2012	Feb	24 5 15 NA Yes R,	I,	P Complete 
Pediatric	hospital,	n	=	8         
 1 F 2013	Jan	28 4 25 ND Yes None Unknown 
 2 M 2012	Jun	15 8 20 ND Yes None Unknown 
 3 M 2012	Mar	25 15 17 ND Yes None Unknown 
 4 M 2012	Jan	28 6 21 ND Yes None Unknown 
 5 M 2013	Jan	28 4 21 ND Yes None Cured 
 6 M 2012	Jun	28 8 25 ND Yes None Unknown 
 7 M 2013	Mar	28 5 15 ND No None Cured 
 8 F 2013	Jun	8 1 17 ND No None Cured 
*BCG,	bacillus	Calmette-Guérin vaccine;	Pos,	positive;	E,	ethambutol;	I,	isoniazid;	P,	pyrazinamide;	R,	rifampin;	NA,	not	available;	ND,	not	done;	NCTLD,	
National	Center	for	Tuberculosis	and	Lung	Diseases. 
†For all patients, type of BCG strain used was Danish SSI (Statens Serum Institute, Copenhagen, Denmark). 




of healing of suppurative nodes and is the only evidence-
based effective treatment (9). Surgical excision remains 
controversial because of potentially high rates of signifi-
cant scarring (10). For nonsuppurative lymphadenitis, a 
watch-and-wait approach is recommended because most 
resolve rapidly (8).
Given our findings, the National TB Program in Geor-
gia subsequently created a management protocol. This 
protocol recommends no intervention for nonsuppurative 
lymphadenitis and needle aspiration for suppurative local 
lymphadenitis.
In summary, we found an increasing rate of BCG-as-
sociated lymphadenitis after a shift to exclusive BCG SSI 
vaccine use in Georgia. Countries with a BCG vaccina-
tion policy should have a clear protocol on management of 
BCG vaccine–related adverse events to avoid inappropriate 
treatment in children.
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To the Editor: Hepatitis E is a viral hepatitide that is 
endemic in many developing countries. In its classic form, 
it results from ingesting fecally contaminated water that 
carries hepatitis E virus (HEV), and it frequently resolves 
without treatment. When hepatitis E is imported to the 
United States, it originates mainly from persons who have 
acquired HEV genotype 1 infection from South Asia (1). 
We report imported HEV genotype 4 infection (Technical 
Appendix Figure, panel A) in a patient during which cir-
rhosis and fatal hepatic decompensation ensued.
The patient was a 68-year-old man of Chinese ethnicity 
who had been a California resident since 1985. He sought 
treatment for mild jaundice in April 2013 in Hong Kong, 
where he had been staying for 7 weeks. Sixteen years be-
fore, he had undergone orthotopic liver transplantation at 
Stanford University Medical Center (Palo Alto, California, 
USA) for hepatitis B cirrhosis. Since then, he had received 
entecavir and tacrolimus for maintenance and had been 
vaccinated against hepatitis A virus. Until his current ill-
ness, routine liver function tests had not indicated hepatic 
dysfunction (values in November 2012: alanine amino-
transferase 2 IU/L, aspartate aminotransferase 24 IU/L, 
alkaline phosphatase 67 IU/L, total bilirubin 0.5 mg/dL).
When the patient returned to the United States, 3 weeks 
after onset of jaundice, the initial work-up showed the fol-
lowing values: alanine aminotransferase 149 IU/L, aspar-
tate aminotransferase 59 IU/L, alkaline phosphatase 193 
IU/L, total bilirubin 2.8 mg/dL (online Technical Appendix 
Figure, panel B, http://wwwnc.cdc.gov/EID/article/21/9/ 
15-0300-Techapp1.pdf). Hepatitis B virus DNA and anti-
nuclear antibodies were not detected, and the tacrolimus 
level was stable. Ultrasound revealed a normal transplanted 
liver. A liver biopsy specimen showed mild portal, biliary, 
and lobular inflammation and early biliary injury (Figure, 
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	21,	No.	9,	September	2015	 1679
LETTERS
